Novel Treatments in HER2-Positive Breast Cancer

Publication
Video
Supplements and Featured PublicationsTherapeutic Changes in HER2+ Breast Cancer
Volume 1
Issue 1

OncLive interviewed experts on novel treatments in HER2-positive breast cancer. 

OncLive interviewed experts on novel treatments in HER2-positive breast cancer.

Supported by an unrestricted educational grant by Daiichi Sankyo

Articles in this issue
Novel Treatments in HER2-Positive Breast Cancer
Novel Treatments in HER2-Positive Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Related Content
Robert A. Winn, MD, FAACR, of VCU

The AACR Releases a Call to Action and Key Statistics in Cancer Disparities Progress Report 2024

May 18th 2024
Article
D. Ross Camidge, MD, PhD; İlker Arslan, MD, United States medical head, TDR Lung, AstraZeneca

Camidge and Arslan Calculate the “Impact Factor” of a Career in Medicine

May 16th 2024
Podcast
Carlos Barrios, MD

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024
Article
Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

May 13th 2024
Podcast
Sibylle Loibl, MD, PhD, chair, German Breast Group, chief executive officer, GBG Forschungs GmbH

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024
Article
Sattva S. Neelapu, MD

CAR T-Cell Agents Offer Efficacy in Lymphoma, But Additional Approaches Are Needed to Overcome Resistance

May 17th 2024
Article